Cross-Sector entity
regulation is the sole category represented across all 1 tracked stories. MBP134 is most often covered alongside Africa Centres for Disease Control and Prevention (Africa CDC), which appears in 1 of these 1 story. Each carries 1 original source on average.
1 verified story tracked
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. MBP134 is most often covered alongside Africa Centres for Disease Control and Prevention (Africa CDC), which appears in 1 of these 1 story. Each carries 1 original source on average. We currently track 1 Cross-Sector story that mention MBP134, all published on July 25, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MBP134. Shared-story counts are live from our verified record — not editorial picks.
WHO reveals outbreak toll
WHO Director-General announces 1,400+ cases and 438 deaths, confirming the trial's start and expressing hope for effective therapies.
Trial launch and first enrollment
Researchers begin the first-ever Ebola treatment trial for Bundibugyo virus at Bunia's Evangelical Medical Center, enrolling the first participant to evaluate remdesivir and MBP134.
A WHO-backed clinical trial in conflict-hit Congo is testing remdesivir and MBP134 for the Bundibugyo strain, spotlighting the extreme operational challenges of providing care and conducting research in fragile health systems.
Source: sun-sentinel.com
